Re:Search Institution Members
Choose one option to export the data.
Approximately 11,000 people per month die, and approximately 450,000 people per year suffer life-altering injuries such as amputation and permanent disability, due to snakebite envenoming. Professor Nicholas Casewell, a Wellcome Trust research fellow at the Centre of Snakebite Research and Interventions (CSRI), Liverpool School of Tropical Medicine, is working on innovative approaches to discover and develop the next generation of treatments for snakebites. To support these efforts, Johnson & Johnson will be sharing its diverse compound library and a targeted set of compounds to potentially identify novel inhibitors of the toxic components of snake venom.
Johnson & Johnson is sharing its Jump-stARter library with Dr. Peter Myler at Seattle Children’s Research Institute (SCRI) for screening for leishmaniasis drug discovery. Under the umbrella of the Seattle Structural Genomics Center for Infectious Disease, SCRI is partnering with the University of Washington’s Dr. Wes Van Voorhis to carry out the screening.
Dr. Stenio Fragoso, Head of the Laboratory of Molecular Biology of Trypanosomatids at Fundação Oswaldo Cruz (Fiocruz), is interested in testing inhibitors against recombinant T. cruzi Topoisomerase II. To initiate these studies, Dr. Fragoso and investigators from Seattle Children’s Research Institute (SCRI) and the National Institute of Allergy and Infectious Diseases (NIAID)-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID; contract HHSN272201700059C) are collaborating to develop constructs to express and purify T. cruzi Topoisomerase II. Once the protein is purified, it will be incorporated into an in vitro assay to identify new drugs for Chagas disease.